fluorescence bound anti-cd4 Search Results


r phycoerythrin labeled goat anti human igg  (Jackson Immuno)
96
Jackson Immuno r phycoerythrin labeled goat anti human igg
<t>IgG</t> (a, c), IgA response (b, d) and neutralizing capacity of IgG (e) towards the indicated SARS-CoV-2 WT (B.1), UK (B.1.1.7), South African (B.1.351) in plasma (a, b, e) or saliva (c, d) from controls (red circles, n=34), individuals on maintenance dialysis (blue circles, n=71) and hemodialyzed individuals on immunosuppressive medication (yellow circles, n=10) 21 days post second vaccination was measured using MULTICOV-AB (a, b, c, d) or an ACE2-RBD competition assay (e). Data is displayed as median fluorescence intensity (MFI) (a-d). Neutralization capacity is displayed as ratio where 1 indicates maximum neutralization and 0 no neutralization (e). Saliva (c, d) was collected from 33 controls (red circles), 65 individuals on maintenance dialysis (blue circles) and from 9 individuals on maintenance dialysis and immunosuppressive medication (yellow circles). Boxes represent the median, 25th and 75th percentiles, whiskers show the largest and smallest non-outlier values. Outliers were determined by 1·5 times IQR. Statistical significance was calculated by Mann-Whitney-U (two-sided). Significance was defined as * <0·01, ** <0·001, *** <0·0001 or n.s.>0·01.
R Phycoerythrin Labeled Goat Anti Human Igg, supplied by Jackson Immuno, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+bound+anti-cd4/med_rxiv__2021__05__26__21257860-52-12-16?v=Jackson+Immuno
Average 96 stars, based on 1 article reviews
r phycoerythrin labeled goat anti human igg - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

Image Search Results


IgG (a, c), IgA response (b, d) and neutralizing capacity of IgG (e) towards the indicated SARS-CoV-2 WT (B.1), UK (B.1.1.7), South African (B.1.351) in plasma (a, b, e) or saliva (c, d) from controls (red circles, n=34), individuals on maintenance dialysis (blue circles, n=71) and hemodialyzed individuals on immunosuppressive medication (yellow circles, n=10) 21 days post second vaccination was measured using MULTICOV-AB (a, b, c, d) or an ACE2-RBD competition assay (e). Data is displayed as median fluorescence intensity (MFI) (a-d). Neutralization capacity is displayed as ratio where 1 indicates maximum neutralization and 0 no neutralization (e). Saliva (c, d) was collected from 33 controls (red circles), 65 individuals on maintenance dialysis (blue circles) and from 9 individuals on maintenance dialysis and immunosuppressive medication (yellow circles). Boxes represent the median, 25th and 75th percentiles, whiskers show the largest and smallest non-outlier values. Outliers were determined by 1·5 times IQR. Statistical significance was calculated by Mann-Whitney-U (two-sided). Significance was defined as * <0·01, ** <0·001, *** <0·0001 or n.s.>0·01.

Journal: medRxiv

Article Title: Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis

doi: 10.1101/2021.05.26.21257860

Figure Lengend Snippet: IgG (a, c), IgA response (b, d) and neutralizing capacity of IgG (e) towards the indicated SARS-CoV-2 WT (B.1), UK (B.1.1.7), South African (B.1.351) in plasma (a, b, e) or saliva (c, d) from controls (red circles, n=34), individuals on maintenance dialysis (blue circles, n=71) and hemodialyzed individuals on immunosuppressive medication (yellow circles, n=10) 21 days post second vaccination was measured using MULTICOV-AB (a, b, c, d) or an ACE2-RBD competition assay (e). Data is displayed as median fluorescence intensity (MFI) (a-d). Neutralization capacity is displayed as ratio where 1 indicates maximum neutralization and 0 no neutralization (e). Saliva (c, d) was collected from 33 controls (red circles), 65 individuals on maintenance dialysis (blue circles) and from 9 individuals on maintenance dialysis and immunosuppressive medication (yellow circles). Boxes represent the median, 25th and 75th percentiles, whiskers show the largest and smallest non-outlier values. Outliers were determined by 1·5 times IQR. Statistical significance was calculated by Mann-Whitney-U (two-sided). Significance was defined as * <0·01, ** <0·001, *** <0·0001 or n.s.>0·01.

Article Snippet: Bound antibodies were detected following a 45 min incubation at 21°C with R-phycoerythrin labeled goat-anti-human IgG (Jackson ImmunoResearch Labs, United Kingdom, Cat# 109-116-098, Lot# 148837, RRID: AB_2337678, used at 3 µg/mL) or IgA (Jackson ImmunoResearch Labs, Cat# 109-115-011, Lot# 143454, RRID: AB_2337674, used at 5 µg/mL) as secondary antibodies.

Techniques: Competitive Binding Assay, Fluorescence, Neutralization, MANN-WHITNEY

T-cell responses assessed by IGRA for IFNγ (mIU/mL) and B-cell responses assessed by MULTICOV-AB IgG binding to WT RBD B.1 (a) or ACE2-WT RBD (B.1) competition assay (b) were plotted for correlation analysis in the vaccinated control group (red circles, n=34), in the vaccinated hemodialyzed group (blue circles, n=71) and in hemodialyzed individuals on additional immunosuppressive medication (yellow circles, n=10). Correlation was calculated using Spearman’s coefficient.

Journal: medRxiv

Article Title: Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis

doi: 10.1101/2021.05.26.21257860

Figure Lengend Snippet: T-cell responses assessed by IGRA for IFNγ (mIU/mL) and B-cell responses assessed by MULTICOV-AB IgG binding to WT RBD B.1 (a) or ACE2-WT RBD (B.1) competition assay (b) were plotted for correlation analysis in the vaccinated control group (red circles, n=34), in the vaccinated hemodialyzed group (blue circles, n=71) and in hemodialyzed individuals on additional immunosuppressive medication (yellow circles, n=10). Correlation was calculated using Spearman’s coefficient.

Article Snippet: Bound antibodies were detected following a 45 min incubation at 21°C with R-phycoerythrin labeled goat-anti-human IgG (Jackson ImmunoResearch Labs, United Kingdom, Cat# 109-116-098, Lot# 148837, RRID: AB_2337678, used at 3 µg/mL) or IgA (Jackson ImmunoResearch Labs, Cat# 109-115-011, Lot# 143454, RRID: AB_2337674, used at 5 µg/mL) as secondary antibodies.

Techniques: Binding Assay, Competitive Binding Assay